PARIS (Reuters) - French pharmaceutical firm Nicox unveiled positive Phase III results for its glaucoma drug on Thursday and said, if approved by regulators, the product could reach peak annual sales of over $1 billion worldwide. Shares in the company shot up as much as 26 percent on the news, giving the company a market capitalization of around 205 million euros ($261.5 million). Nicox estimates that the drug, called Vesneo (latanoprostene bunod) and designed to treat glaucoma and ocular hypertension, could reach peak annual sales of around $500 million in the United States alone. ...
via Health News Headlines - Yahoo News http://ift.tt/Yb4gzM
via Health News Headlines - Yahoo News http://ift.tt/Yb4gzM
No comments:
Post a Comment